WO2004008945A2 - Uveoscleral drainage device - Google Patents
Uveoscleral drainage device Download PDFInfo
- Publication number
- WO2004008945A2 WO2004008945A2 PCT/US2003/022832 US0322832W WO2004008945A2 WO 2004008945 A2 WO2004008945 A2 WO 2004008945A2 US 0322832 W US0322832 W US 0322832W WO 2004008945 A2 WO2004008945 A2 WO 2004008945A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- shunt
- elongate body
- insertion head
- spaced
- elongate
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
- A61F9/007—Methods or devices for eye surgery
- A61F9/00781—Apparatus for modifying intraocular pressure, e.g. for glaucoma treatment
Definitions
- the invention relates to eye implants, more particularly, to an ophthalmic shunt and method of using same for use in enhancing uveoscleral drainage in the eye to lower eye pressure.
- Glaucoma a leading cause of world blindness, is a group of disorders, characterized by irreversible damage to the optic nerve, or glaucomatous optic neuropathy, in which elevated intraocular pressure is the main causative risk factor. The only proven way to prevent the blindness of glaucoma is to control the intraocular pressure.
- Clinical management of intraocular pressure can be achieved medically or surgically.
- Modern medical therapy for glaucoma began in the 1870s, with the introduction of pilocarpine and other cholinergic agonists, hi the twentieth century, several compounds were introduced, such as alpha-2 agonists, beta-adrenergic antagonists, topical and systemic carbonic anhydrase inhibitors, and prostaglandins.
- alpha-2 agonists beta-adrenergic antagonists
- topical and systemic carbonic anhydrase inhibitors and prostaglandins.
- glaucoma medication are not available or practical in many parts of the world, and are inadequate in many patients, despite availability. Hence the need for surgical methods to control the intraocular pressure.
- Control of intraocular pressure can be achieved surgically by reducing the production of aqueous humor or by increasing its outflow.
- Operations to reduce production referred to collectively as cyclodestructive surgery, destroy a portion of the ciliary body, the source of aqueous humor.
- Destructive elements over the years have included diathermy, cryotherapy and, most recently, laser energy. While these operations are effective in lowering the intraocular pressure, and are beneficial in desperate cases, they have a high complication rate, including inflammation and further reduction in visual acuity.
- aqueous humor leaves the eye by many routes. Some goes posteriorly through the vitreous body to the retina, while most circulates in the anterior segment of the eye, nourishing avascular structures such as the lens and cornea, before outflow by two main routes: canalicular or uveoscleral.
- the canalicular also referred to as the trabecular or conventional, route is the main mechanism of outflow, accounting for approximately 80% of aqueous egress from the normal eye.
- the route is from the anterior chamber angle (formed by the iris and cornea), through the trabecular meshwork, into Schlemm's canal.
- Schlemm's canal is a 360° channel just peripheral to meshwork. It is connected to intrascleral outlet channels that take the aqueous through the sclera to reunite with the blood stream in the episcleral veins.
- the uveoscleral route is less clear with regard to anatomy and physiologic significance, but probably accounts for 10-20% of aqueous outflow in the normal human eye.
- the uveoscleral pathway begins in the anterior chamber angle.
- the aqueous is absorbed by portions of the peripheral iris, the ciliary body and probably the trabecular meshwork, from whence it passes posteriorly through the longitudinal muscle of the ciliary body to the suprachoroidal space (between the choroids and sclera).
- Aqueous in the suprachoroidal space may pass as far posteriorly as the optic nerve and leave the eye through a variety of emissaria around nerves and vessels in the sclera.
- the ideal glaucoma operation would be to re-establish normal canalicular flow into Schlemm's canal, hi some forms of glaucoma this is possible, such as the iridectomy (introduced in the 1850s) for pupillary block glaucoma and goniotomy and trabeculotomy (introduced in the mid-twentieth century) for congenital glaucoma.
- Schlemm's canal and sclera Aqueous flows through the fistula to create a pool beneath the elevated conjunction (called a bleb), through which it filters to wash away in the tear film.
- a bleb the elevated conjunction
- the basic operation, in a variety of modified forms, has now been the preferred glaucoma procedure for nearly 100 years, despite serious limitations.
- Limitations of filtering surgery include failure due to fibrotic closure of the fistula. Of even greater concern are the complications associated with excessive outflow, which include an intraocular pressure that is too low (hypotony) and a conjunctival filtering bleb that becomes too thin, with leakage and the risk of infection (endophthalmitis) .
- Drainage implant surgery was developed primarily to overcome the problem of fistula closure, since a conduit passes from the anterior chamber angle, through the fistula, to a plate beneath the conjuctiva.
- these operations are also complicated by early hypotony and late failure due to obstruction of the conduit or excessive fibrosis over the plate.
- the uveoscleral pathway may only account for 10-20% of aqueous outflow in the normal state, there is evidence that it can be enhanced to accommodate a significantly greater percentage of outflow.
- topical prostaglandins which work nearly exclusively by increasing uveoscleral outflow, can lower the intraocular pressure by 30-50% in some patients. Even more compelling are the results of early surgical attempts to enhance uveoscleral outflow.
- an ophthalmic shunt suitable for implantation in an eye is provided.
- the shunt has an elongate body and a conduit for conducting aqueous humor from an anterior chamber of the eye to the suprachoroidal space of the eye.
- the elongate body has a forward end and an insertion head that extends from the forward end.
- the insertion head defines a shearing edge suitable for cutting eye tissue engaged thereby.
- the forward end and the insertion head of the body define a shoulder surface.
- the elongate body may have a substantially fusiform cross- sectional shape.
- the elongate body may also have an arcuate shape along at least a portion of its length with a radius of curvature suitable for extending along the curvature of the sclera of the eye.
- the conduit of the shunt has a first end defined on a portion of a top surface of the insertion head.
- the conduit also extends through the body from the forward end to a back end thereof.
- the first end of the conduit is spaced from both of the shearing edge and the shoulder of the body.
- the conduit may be formed of a porous wicking member suitable for regulating the flow of aqueous humor from a first end to a second end of the conduit.
- the wicking member may be disposed within at least a portion of the conduit.
- the shunt may be readily implanted within the eye of a patient in order to reduce the intraocular pressure within the eye.
- a first incision in and through the conjunctiva and the sclera at a position posterior to the limbus is made.
- the shunt is then grasped by the surgeon with, for example, a surgical tool, whereupon the insertion head of the shunt is passed through the first incision and into the supraciliary space of the eye.
- at least a portion of the shearing edge of the insertion head is inserted into and through the anterior chamber angle into the anterior chamber of the eye.
- the first end of the conduit When the insertion head is inserted within the anterior chamber, the first end of the conduit is placed in fluid communication with the anterior chamber and the second end of the conduit is placed in fluid communication with the suprachoroidal space.
- aqueous humor is allowed to flow from the anterior chamber of the eye to the suprachoroidal space, which allows the intraocular pressure in the eye to be lowered.
- the shunt prevents cleft closure and controls the rate of aqueous flow into the suprachoroidal space via the conduit, which prevents hypotony.
- Fig. 1 is a partial cross-sectional view of an eye showing the normal aqueous flow of aqueous humor though the anterior chamber of the eye.
- Figs. 2A and 2B are partial top views of an eye showing the prior art cyclodialysis operation and the typical result.
- Fig. 3 A is a perspective view of a first embodiment of the present invention.
- Fig. 3B is a perspective view of the embodiment shown in Fig. 3 A being grasped by a surgical tool.
- Fig. 3C is a cross-sectional view of the embodiment shown in Fig. 3 A taken along line 3A.
- Fig. 4A is a perspective view of an elongate body of a second embodiment of the present invention.
- Fig. 4B is a perspective view of an elongate conduit of the second embodiment of the present invention.
- Fig. 4C is a perspective view of the second embodiment with the elongate conduit shown in Fig. 4B disposed within a portion of the elongate body and overlying a portion of a top surface of an insertion head.
- Fig. 4D is a perspective view of the second embodiment shown in Fig. 4C being grasped by a surgical tool.
- Fig. 5 A is a perspective view of an elongate body of a third embodiment of the present invention.
- Fig. 5B is a perspective view of an elongate wicking member having an inlet end and an outlet end.
- Fig. 5C is a perspective view of the third embodiment with the elongate wicking member shown in Fig. 5B disposed within a slit of the elongate body and overlying a portion of a top surface of an insertion head.
- Fig. 5D is a perspective view of the third embodiment of Fig. 5C being grasped by a surgical tool.
- Fig. 6A is a partial top view of an eye having an implant, according to the present invention, being positioned into the anterior chamber of the eye.
- Fig. 6B is an enlarged cross-sectional detail view of the implant of Fig. 6 A.
- Fig. 7A is a partial top view of an eye in which an implant according to the present invention is located therein postoperatively.
- Fig. 7B is an enlarged cross-sectional detail view of the implant of Fig. 7A. DETAILED DESCRIPTION OF THE INVENTION
- the implant or shunt 10 of the present invention comprises an uveoscleral drainage device that is adapted for implantation within an eye of a patient.
- the shunt 10 comprises an elongate body 20 and a conduit 40.
- the elongate body has a forward end 22, a spaced back end 24, and extends along a longitudinal axis L.
- the body also has an insertion head 26 that extends generally longitudinally from the forward end thereof.
- the elongate body further has a first elongate edge 21 and a second elongate edge 23 that extend respectively from the forward end to the back end of the body.
- the insertion head is adapted for insertion into the anterior chamber of the eye and defines a shearing edge 28 constructed and arranged for cutting eye tissue engaged thereby.
- the shearing edge of the insertion head may have an arcuate shape.
- other shapes such as, for example, chisel shapes, scalpel shapes, and the like, are contemplated for the shearing edge.
- the juncture of the insertion head 26 against the forward end 22 of the body defines a shoulder surface 30 thereon.
- the insertion head has a base portion 32 having a first width and where the respective first and second elongate edges are spaced apart a second width that is greater than the first width.
- the shoulder surface 30 of the body is adapted to engage tissue portions of the anterior chamber angle of the eye that are adjacent an interior surface of the interior chamber. The shoulder surface 30 also aids is limiting the anterior movement or displacement of the device when implanted, which helps prevent the forward end 22 of the drainage device from penetrating and entering the anterior chamber.
- the base portion of the insertion head 26 extends substantially co-planar to a lower surface 34 of the elongate body. Alternatively, the insertion head 26 may extend from a portion of the forward end that is spaced from the circumferential edge of the forward end. In this example, the shoulder surface 30 would extend about the periphery of the base portion of the insertion head.
- the body 20 has a length from the forward end to the back end of such extent to extend from proximate the interior surface of the anterior chamber to the suprachoroidial space of the eye.
- the back end 24 of the body is adapted for insertion within the suprachoroidial space of the eye.
- the body may be substantially planar or may have an arcuate shape that is adapted to extend along a portion of the curvature of the sclera of the eye.
- the body is generally thin to provide a less irritating fit within the eye.
- the elongate body 20 has a substantially fusiform cross- sectional shape.
- the conduit 40 has a first end 42 and a spaced second end 44.
- a portion of the conduit is defined on a portion of a top surface 27 of the insertion head 26 with the remaining portion defined within the elongate body 20 and extending from the forward end to the back end thereof.
- the first end of the conduit is spaced from the shearing edge 28 and is spaced from the shoulder surface 30 of the body.
- the first end 42 of the conduit is positioned at an acute angle with respect to the top surface 27 of the insertion head.
- the conduit is formed integrally with the elongate body.
- the conduit 40 may also be a separate member which is connected to the elongate body.
- the conduit 40 of the present invention comprises an elongate tube 50 having a first end 52 and a spaced second end 54. Further, the elongate body defines a longitudinally extending bore 38 therein. A proximal end of the bore is defined in the forward end of the body and is positioned adjacent the top surface of the insertion head. In use, at least a portion of the tube is positioned within the bore of the body such that the second end 54 of the tube is positioned proximate a distal end of the bore. Further, the first end 52 of the tube extends through the proximal end of the bore and overlies a portion of the top surface 27 of the insertion head.
- the first end 52 of the tube is spaced from both the shearing edge and the shoulder surface of the body 20.
- the tube 50 positioned within the bore of the body forms the "conduit" 40 described in reference to Figs. 3A-3C.
- the conduit may comprise a wicking member 60 that is constructed and arranged for regulating the flow of aqueous humor from an inlet end 62 to an outlet end 64 of the wicking member.
- This wicking member may, in one example, be a porous material suitable for insertion within at least a portion of the conduit.
- Such a wicking member 60 may be readily used in the embodiment shown in Fig. 3 A.
- the wicking member 60 may be a porous material surrounded by a non-porous sheath. Such a sheathed wicking member could be used as the "tube" in the embodiment shown in Figs. 4A - 4C.
- the wicking member 60 could be formed from a plurality of tubular conduits. The flow rate through the wicking member may be controlled selectively choosing among the porosity of the material used, the length of the wicking member, and/or the number and relative size of the tubular conduits used in the respective examples. The use of a wicking member 60 allows for the variation of outflow required from the conduit to relieve undesired intraocular pressure.
- FIG. 5 A - 5C an alternative embodiment of the device is shown that includes a wicking member 60.
- an upper surface 36 of the elongate body defines a longitudinally extending slit 39.
- the slit extends from the forward end to the back end of the body.
- the wicking member 60 is constructed and arranged so that the flow of aqueous humor from the inlet end 62 to the outlet end 64 is regulated and aqueous humor entering the inlet end can only exit the outlet end, which is placed in communication with the suprachoroidal space.
- the wicking member 60 is positioned within at least a portion of the slit of the body and overlies a portion of the top surface 27 of the insertion head 26.
- the inlet end 62 of the wicking member is spaced from the shearing edge of the body and, in one example, the inlet end is positioned at an acute angle with respect to the top surface of the insertion head.
- the elongate body provides a means for grasping the body by a surgical tool such as, for example, forceps and the like.
- a surgical tool such as, for example, forceps and the like.
- at least one planar surface 70 constructed and arranged for grasping by the surgical tool is defined on at least a portion of at least one of the respective upper and lower surfaces of the elongate body.
- a portion of the slit in the elongate body forms one planar surface.
- the elongate body 20 may define a longitudinally extending groove 80, extending from the back end of the body, in the exterior surface of the body.
- the groove 80 is constructed and arranged for grasping by the surgical tool.
- the groove may be positioned in the upper surface or in the lower surface of the body.
- a second longitudinally extending groove or a planar surface may be defined in the opposite spaced respective upper or lower surface to facilitate secure grasping of the device.
- any combination of planar surfaces and/or grooves on the respective upper and lower surfaces may be used to provide suitable grasping surfaces for the surgical tool.
- the shunt may be fixed to a portion of the sclera of the eye.
- the shunt may have at least one stitching loop 100 defined in the elongate body. Sutures can be passed through the loop and secured to the sclera.
- the elongate body has a pair of spaced notches 110 that are constructed and arranged for facilitating suturing of the elongate body to eye tissue.
- one notch of the pair of spaced notches is defined in each respective elongate edge of the body. Further, each notch may have a keyhole shape.
- the body has at least a pair of spaced bores 120 extending between the upper and lower surfaces of the body.
- a suture can be passed through the bores for subsequent securing to the sclera.
- at least one suture may be preloaded into the stitching loop, notches, bores, and the like of the device prior to inserting the device into the eye.
- the device of the present invention is designed to be implanted through an incision or cleft formed in the anterior chamber angle of the eye by the shearing edge of the shunt 10.
- the method and device should be readily accepted by general ophthalmologists who can incorporate the use of the implant easily into already established surgical techniques. It would thus present an attractive and cost effective technological alternative for an eye surgeon. Because the procedure can be done quickly with minimum instrumentation, the device of the present invention would be especially advantageous in developing nations, where glaucoma is a leading cause of blindness. Turning now to Figs. 6A - 7B, the surgical method for implanting the device of the present invention into an eye will be explained.
- a first incision or slit is made through the conjunctiva and the sclera at a location rearward of the limbus, that is, posterior to the region of the sclera at which the opaque white sclera starts to become clear cornea.
- the first incision is made about 3mm posterior to the limbus.
- the first incision is made slightly larger than the width of the implant device.
- a conventional cyclodialysis spatula may be inserted through the first incision into the supraciliary space to confirm correct anatomic position.
- a portion of the upper and lower surfaces of the shunt 10 proximate the back end of the body is then grasped securely by the surgical tool, for example, a forceps, so that the forward end of the shunt is oriented properly.
- the shunt is oriented with the longitudinal axis of the device being substantially co-axial to the longitudinal axis of the grasping end of the surgical tool.
- the shunt 10 is then disposed through the first incision and into the supraciliary space of the eye.
- the shearing edge of the shunt is advanced anteriorly in the supraciliary space and is inserted into and through the anterior chamber angle of the eye.
- the shearing edge of the insertion head passes preferably between the scleral spur and the ciliary body posterior to the trabecular meshwork.
- the shunt is continually advanced anteriorly until a portion of the insertion head and the first end of the conduit is disposed within the anterior chamber of the eye.
- the first end of the conduit is placed into fluid communication with the anterior chamber of the eye.
- the back end of the elongate body is disposed into the suprachoroidal space of the eye so that the second end of the conduit is placed into fluid communication with the suprachoroidal space.
- the shoulder surface of the forward end of the shunt is seated proximate an interior surface of the supraciliary space and is not introduced into the anterior chamber.
- the shoulder surface aids in forming a tight seal to prevent leakage of aqueous humor around the device as well as helping to prevent unwanted further anterior movement of the shunt.
- the shape of the cleft formed by the insertion head forms a tight seal about the exterior surface of the body, and, if used, the fusiform cross-sectional shape of the body prevents gaping of the formed cleft on either elongate edge of the shunt.
- the shunt is then sutured to a portion of the sclera to aid in fixating the shunt.
- the first incision is subsequently sutured closed.
- the suture used to fixate the shunt may also be used to close the first incision.
- the drainage device forms a cyclodialysis with the conduit providing transverse communication of aqueous humor through the shunt along its length. Aqueous humor thus delivered to the suprachoroidal space will then be absorbed therein, and additional reduction in pressure within the eye is to be expected.
- the device may be made from any biological inert and biocompatible materials having the desired characteristics.
- the elongate body may be substantially rigid or may be substantially resilient and semi-rigid. Further, the exterior surface of the elongate body is non-porous. Various medically suitable acrylics and other plastics are considered appropriate.
- the finish of the device should be to the standard - 13 -
- the device may be made by conventional liquid injection molding or transfer molding process.
Abstract
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
MXPA05000807A MXPA05000807A (en) | 2002-07-19 | 2003-07-21 | Uveoscleral drainage device. |
BRPI0312816-4A BR0312816A (en) | 2002-07-19 | 2003-07-21 | implantable ophthalmic shunt in one eye and method of lowering eye pressure and treating glaucoma in one eye |
EP03765883A EP1534363B1 (en) | 2002-07-19 | 2003-07-21 | Uveoscleral drainage device |
DE60325606T DE60325606D1 (en) | 2002-07-19 | 2003-07-21 | UVEKLERAL DRAINAGE DEVICE |
AU2003256657A AU2003256657A1 (en) | 2002-07-19 | 2003-07-21 | Uveoscleral drainage device |
CA2493010A CA2493010C (en) | 2002-07-19 | 2003-07-21 | Uveoscleral drainage device |
HK06104686.5A HK1084313A1 (en) | 2002-07-19 | 2006-04-19 | Uveoscleral drainage device |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US39756502P | 2002-07-19 | 2002-07-19 | |
US60/397,565 | 2002-07-19 |
Publications (3)
Publication Number | Publication Date |
---|---|
WO2004008945A2 true WO2004008945A2 (en) | 2004-01-29 |
WO2004008945A9 WO2004008945A9 (en) | 2004-06-10 |
WO2004008945A3 WO2004008945A3 (en) | 2005-02-03 |
Family
ID=30771081
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2003/022832 WO2004008945A2 (en) | 2002-07-19 | 2003-07-21 | Uveoscleral drainage device |
Country Status (13)
Country | Link |
---|---|
US (2) | US7041077B2 (en) |
EP (3) | EP2039380B1 (en) |
CN (2) | CN101791258A (en) |
AT (2) | ATE419026T1 (en) |
AU (1) | AU2003256657A1 (en) |
BR (1) | BR0312816A (en) |
CA (2) | CA2493010C (en) |
DE (1) | DE60325606D1 (en) |
ES (1) | ES2320121T3 (en) |
HK (1) | HK1084313A1 (en) |
MX (1) | MXPA05000807A (en) |
WO (1) | WO2004008945A2 (en) |
ZA (1) | ZA200501458B (en) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7282046B2 (en) | 2004-01-22 | 2007-10-16 | Peter M. Adams, Doug P. Adams, and John Sullivan, Collectively as the Stockholder Representative Committee | Glaucoma treatment method |
WO2008154502A1 (en) * | 2007-06-07 | 2008-12-18 | Yale University | Uveoscleral drainage device |
US7662123B2 (en) | 2002-07-19 | 2010-02-16 | Yale University | Uveoscleral drainage device |
WO2017103818A1 (en) * | 2015-12-16 | 2017-06-22 | Novartis Ag | Devices and methods for a cannula-delivered treatment material application device |
WO2019051475A1 (en) * | 2017-09-11 | 2019-03-14 | Oregon Health & Science University | Glaucoma tube implant with modulated flow |
US10285853B2 (en) | 2013-03-15 | 2019-05-14 | Glaukos Corporation | Systems and methods for delivering an ocular implant to the suprachoroidal space within an eye |
US10828195B2 (en) | 2006-11-10 | 2020-11-10 | Glaukos Corporation | Uveoscleral shunt and methods for implanting same |
Families Citing this family (136)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8313454B2 (en) | 1997-11-20 | 2012-11-20 | Optonol Ltd. | Fluid drainage device, delivery device, and associated methods of use and manufacture |
US6203513B1 (en) * | 1997-11-20 | 2001-03-20 | Optonol Ltd. | Flow regulating implant, method of manufacture, and delivery device |
EP2260804B2 (en) | 1999-04-26 | 2022-03-02 | Glaukos Corporation | Trabeculotomy device for treating glaucoma |
US20050119737A1 (en) * | 2000-01-12 | 2005-06-02 | Bene Eric A. | Ocular implant and methods for making and using same |
US7708711B2 (en) | 2000-04-14 | 2010-05-04 | Glaukos Corporation | Ocular implant with therapeutic agents and methods thereof |
US6638239B1 (en) | 2000-04-14 | 2003-10-28 | Glaukos Corporation | Apparatus and method for treating glaucoma |
US7041786B2 (en) | 2001-03-29 | 2006-05-09 | Callisto Pharmaceuticals | Guanylate cyclase receptor agonists for the treatment of tissue inflammation and carcinogenesis |
US7488303B1 (en) * | 2002-09-21 | 2009-02-10 | Glaukos Corporation | Ocular implant with anchor and multiple openings |
US7431710B2 (en) | 2002-04-08 | 2008-10-07 | Glaukos Corporation | Ocular implants with anchors and methods thereof |
ES2304438T3 (en) | 2001-04-07 | 2008-10-16 | Glaukos Corporation | GLAUCOMA STENT FOR THE TREATMENT OF GLAUCOMA. |
US7678065B2 (en) | 2001-05-02 | 2010-03-16 | Glaukos Corporation | Implant with intraocular pressure sensor for glaucoma treatment |
US7951155B2 (en) | 2002-03-15 | 2011-05-31 | Glaukos Corporation | Combined treatment for cataract and glaucoma treatment |
US9301875B2 (en) | 2002-04-08 | 2016-04-05 | Glaukos Corporation | Ocular disorder treatment implants with multiple opening |
WO2004026347A2 (en) * | 2002-09-17 | 2004-04-01 | Iscience Surgical Corporation | Apparatus and method for surgical bypass of aqueous humor |
US20040225250A1 (en) | 2003-05-05 | 2004-11-11 | Michael Yablonski | Internal shunt and method for treating glaucoma |
US7207965B2 (en) * | 2003-06-16 | 2007-04-24 | Solx, Inc. | Shunt for the treatment of glaucoma |
US7291125B2 (en) * | 2003-11-14 | 2007-11-06 | Transcend Medical, Inc. | Ocular pressure regulation |
US7364564B2 (en) * | 2004-03-02 | 2008-04-29 | Becton, Dickinson And Company | Implant having MEMS flow module with movable, flow-controlling baffle |
US20050194303A1 (en) * | 2004-03-02 | 2005-09-08 | Sniegowski Jeffry J. | MEMS flow module with filtration and pressure regulation capabilities |
US7226540B2 (en) * | 2004-02-24 | 2007-06-05 | Becton, Dickinson And Company | MEMS filter module |
US20060173399A1 (en) * | 2005-02-01 | 2006-08-03 | Rodgers M S | MEMS flow module with pivoting-type baffle |
US7544176B2 (en) * | 2005-06-21 | 2009-06-09 | Becton, Dickinson And Company | Glaucoma implant having MEMS flow module with flexing diaphragm for pressure regulation |
US7384550B2 (en) * | 2004-02-24 | 2008-06-10 | Becton, Dickinson And Company | Glaucoma implant having MEMS filter module |
US20060206049A1 (en) * | 2005-03-14 | 2006-09-14 | Rodgers M S | MEMS flow module with piston-type pressure regulating structure |
US20060219627A1 (en) * | 2005-03-31 | 2006-10-05 | Rodgers M S | MEMS filter module with concentric filtering walls |
US20060036207A1 (en) * | 2004-02-24 | 2006-02-16 | Koonmen James P | System and method for treating glaucoma |
KR20070033974A (en) * | 2004-04-29 | 2007-03-27 | 아이싸이언스 인터벤셔날 코포레이션 | Apparatus and method for surgical reinforcement of waterproof discharge |
US20100173866A1 (en) * | 2004-04-29 | 2010-07-08 | Iscience Interventional Corporation | Apparatus and method for ocular treatment |
US7862531B2 (en) | 2004-06-25 | 2011-01-04 | Optonol Ltd. | Flow regulating implants |
AU2011253724B2 (en) * | 2004-06-25 | 2013-08-29 | Alcon Inc. | Flow regulating implants |
AR054647A1 (en) | 2005-02-21 | 2007-07-11 | Maldonado Bas Arturo | DEVICE FOR WATER HUMOR DRAINAGE IN GLAUCOMA CASES |
EP3838236A1 (en) | 2006-01-17 | 2021-06-23 | Alcon Inc. | Glaucoma treatment device |
EP1978892B1 (en) * | 2006-01-17 | 2017-11-15 | Novartis Ag | Drug delivery treatment device |
AU2016201445B2 (en) * | 2006-01-17 | 2017-10-26 | Alcon Inc. | Glaucoma treatment device |
US8852137B2 (en) | 2010-11-15 | 2014-10-07 | Aquesys, Inc. | Methods for implanting a soft gel shunt in the suprachoroidal space |
US9095411B2 (en) | 2010-11-15 | 2015-08-04 | Aquesys, Inc. | Devices for deploying intraocular shunts |
US8852256B2 (en) | 2010-11-15 | 2014-10-07 | Aquesys, Inc. | Methods for intraocular shunt placement |
US10085884B2 (en) | 2006-06-30 | 2018-10-02 | Aquesys, Inc. | Intraocular devices |
US8828070B2 (en) | 2010-11-15 | 2014-09-09 | Aquesys, Inc. | Devices for deploying intraocular shunts |
US20120123317A1 (en) * | 2010-11-15 | 2012-05-17 | Aquesys, Inc. | Methods for implanation of glaucoma shunts |
EP2043572B1 (en) * | 2006-06-30 | 2014-12-31 | Aquesys Inc. | Apparatus for relieving pressure in an organ |
US8801766B2 (en) | 2010-11-15 | 2014-08-12 | Aquesys, Inc. | Devices for deploying intraocular shunts |
US8974511B2 (en) | 2010-11-15 | 2015-03-10 | Aquesys, Inc. | Methods for treating closed angle glaucoma |
US8308701B2 (en) | 2010-11-15 | 2012-11-13 | Aquesys, Inc. | Methods for deploying intraocular shunts |
US20120123316A1 (en) | 2010-11-15 | 2012-05-17 | Aquesys, Inc. | Intraocular shunts for placement in the intra-tenon's space |
US8663303B2 (en) | 2010-11-15 | 2014-03-04 | Aquesys, Inc. | Methods for deploying an intraocular shunt from a deployment device and into an eye |
US8721702B2 (en) | 2010-11-15 | 2014-05-13 | Aquesys, Inc. | Intraocular shunt deployment devices |
US8758290B2 (en) | 2010-11-15 | 2014-06-24 | Aquesys, Inc. | Devices and methods for implanting a shunt in the suprachoroidal space |
US8911496B2 (en) | 2006-07-11 | 2014-12-16 | Refocus Group, Inc. | Scleral prosthesis for treating presbyopia and other eye disorders and related devices and methods |
KR101351863B1 (en) * | 2006-07-11 | 2014-01-15 | 리포쿠스 그룹 인코포레이티드 | Screral prosthesis for treating presbyopia and other eye disorders and related devices and methods |
AU2013206830B2 (en) * | 2006-07-11 | 2015-09-24 | Refocus Group, Inc. | Scleral prosthesis for treating presbyopia and other eye disorders and related devices and methods |
CN101772513B (en) | 2007-06-04 | 2013-11-13 | 协同医药品公司 | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
US8672870B2 (en) | 2007-07-17 | 2014-03-18 | Transcend Medical, Inc. | Ocular implant with hydrogel expansion capabilities |
US20170360609A9 (en) | 2007-09-24 | 2017-12-21 | Ivantis, Inc. | Methods and devices for increasing aqueous humor outflow |
US7740604B2 (en) | 2007-09-24 | 2010-06-22 | Ivantis, Inc. | Ocular implants for placement in schlemm's canal |
US20090082862A1 (en) | 2007-09-24 | 2009-03-26 | Schieber Andrew T | Ocular Implant Architectures |
US8734377B2 (en) | 2007-09-24 | 2014-05-27 | Ivantis, Inc. | Ocular implants with asymmetric flexibility |
US8512404B2 (en) | 2007-11-20 | 2013-08-20 | Ivantis, Inc. | Ocular implant delivery system and method |
US8808222B2 (en) | 2007-11-20 | 2014-08-19 | Ivantis, Inc. | Methods and apparatus for delivering ocular implants into the eye |
US8109896B2 (en) | 2008-02-11 | 2012-02-07 | Optonol Ltd. | Devices and methods for opening fluid passageways |
EP2092916A1 (en) | 2008-02-19 | 2009-08-26 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | A method of treating an ocular pathology by applying high intensity focused ultrasound and device thereof |
CA2717441A1 (en) | 2008-03-05 | 2009-09-11 | Ivantis, Inc. | Methods and apparatus for treating glaucoma |
ES2522968T3 (en) | 2008-06-04 | 2014-11-19 | Synergy Pharmaceuticals Inc. | Guanylate cyclase agonists useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
WO2009149278A1 (en) | 2008-06-04 | 2009-12-10 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
WO2009158524A2 (en) | 2008-06-25 | 2009-12-30 | Transcend Medical, Inc. | Ocular implant with shape change capabilities |
JP2011528375A (en) | 2008-07-16 | 2011-11-17 | シナジー ファーマシューティカルズ インコーポレイテッド | Guanylate cyclase agonists useful for the treatment of gastrointestinal disorders, inflammation, cancer, and other disorders |
US20100056977A1 (en) * | 2008-08-26 | 2010-03-04 | Thaddeus Wandel | Trans-corneal shunt and method |
EP2358304A4 (en) * | 2008-11-19 | 2014-03-26 | Refocus Group Inc | Artificial intraocular lens, altered natural crystalline lens, or refilled natural crystalline lens capsule with one or more scleral prostheses for improved performance |
EP2373296B1 (en) | 2008-12-03 | 2016-08-03 | Synergy Pharmaceuticals Inc. | Formulations of guanylate cyclase c agonists and methods of use |
EP3960135A1 (en) * | 2008-12-05 | 2022-03-02 | Ivantis, Inc. | Apparatus for delivering ocular implants into the eye |
US8425473B2 (en) * | 2009-01-23 | 2013-04-23 | Iscience Interventional Corporation | Subretinal access device |
US20100191177A1 (en) * | 2009-01-23 | 2010-07-29 | Iscience Interventional Corporation | Device for aspirating fluids |
WO2010088258A2 (en) | 2009-01-28 | 2010-08-05 | Transcend Medical, Inc. | Ocular implant with stiffness qualities, methods of implantation and system |
EP2398432B1 (en) | 2009-02-18 | 2017-09-06 | Eye Tech Care | Ultrasound device comprising means to generate ultrasound beam presenting a concave segment shape having a single curvature |
US10206813B2 (en) | 2009-05-18 | 2019-02-19 | Dose Medical Corporation | Implants with controlled drug delivery features and methods of using same |
CN102481171B (en) | 2009-07-09 | 2015-01-28 | 伊万提斯公司 | Single operator device for delivering an ocular implant |
AU2010271218B2 (en) | 2009-07-09 | 2017-02-02 | Alcon Inc. | Ocular implants and methods for delivering ocular implants into the eye |
US20110105986A1 (en) * | 2009-09-21 | 2011-05-05 | Ben Bronstein | Uveoscleral drainage device |
EP2490621A4 (en) | 2009-10-23 | 2013-04-03 | Ivantis Inc | Ocular implant system and method |
US20110105990A1 (en) * | 2009-11-04 | 2011-05-05 | Silvestrini Thomas A | Zonal drug delivery device and method |
US8529492B2 (en) | 2009-12-23 | 2013-09-10 | Trascend Medical, Inc. | Drug delivery devices and methods |
WO2011083358A1 (en) | 2010-01-11 | 2011-07-14 | Eye Tech Care | Device for treating an ocular pathology by applying doses of laser energy |
WO2011163505A1 (en) | 2010-06-23 | 2011-12-29 | Ivantis, Inc. | Ocular implants deployed in schlemm's canal of the eye |
AU2011302006A1 (en) | 2010-09-15 | 2013-03-07 | Synergy Pharmaceuticals Inc. | Formulations of guanylate cyclase C agonists and methods of use |
US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
US8585629B2 (en) | 2010-11-15 | 2013-11-19 | Aquesys, Inc. | Systems for deploying intraocular shunts |
US20160256319A1 (en) | 2010-11-15 | 2016-09-08 | Aquesys, Inc. | Intraocular shunt placement in the suprachoroidal space |
US9668915B2 (en) | 2010-11-24 | 2017-06-06 | Dose Medical Corporation | Drug eluting ocular implant |
EP3685801A1 (en) | 2011-02-04 | 2020-07-29 | ForSight Vision6, Inc. | Intraocular accommodating lens |
US10245178B1 (en) | 2011-06-07 | 2019-04-02 | Glaukos Corporation | Anterior chamber drug-eluting ocular implant |
US8657776B2 (en) | 2011-06-14 | 2014-02-25 | Ivantis, Inc. | Ocular implants for delivery into the eye |
EP3659495B1 (en) | 2011-09-13 | 2022-12-14 | Dose Medical Corporation | Intraocular physiological sensor |
US8852136B2 (en) | 2011-12-08 | 2014-10-07 | Aquesys, Inc. | Methods for placing a shunt into the intra-scleral space |
US9610195B2 (en) * | 2013-02-27 | 2017-04-04 | Aquesys, Inc. | Intraocular shunt implantation methods and devices |
US8765210B2 (en) | 2011-12-08 | 2014-07-01 | Aquesys, Inc. | Systems and methods for making gelatin shunts |
US10080682B2 (en) | 2011-12-08 | 2018-09-25 | Aquesys, Inc. | Intrascleral shunt placement |
US9808373B2 (en) | 2013-06-28 | 2017-11-07 | Aquesys, Inc. | Intraocular shunt implantation |
US8663150B2 (en) | 2011-12-19 | 2014-03-04 | Ivantis, Inc. | Delivering ocular implants into the eye |
US9101444B2 (en) | 2012-01-12 | 2015-08-11 | Innfocus, Inc. | Method, surgical kit and device for treating glaucoma |
CN103284831A (en) * | 2012-02-29 | 2013-09-11 | 北京大学第三医院 | Foldable glaucoma aqueous humor drainage device |
US9358156B2 (en) | 2012-04-18 | 2016-06-07 | Invantis, Inc. | Ocular implants for delivery into an anterior chamber of the eye |
US10085633B2 (en) | 2012-04-19 | 2018-10-02 | Novartis Ag | Direct visualization system for glaucoma treatment |
US9241832B2 (en) | 2012-04-24 | 2016-01-26 | Transcend Medical, Inc. | Delivery system for ocular implant |
US8888734B2 (en) * | 2012-06-05 | 2014-11-18 | Alcon Research, Ltd. | Functionally graded material tube and method for use of the same in implantation |
WO2014043698A2 (en) | 2012-09-17 | 2014-03-20 | Transcend Medical, Inc. | Expanding ocular implant devices and methods |
US9763829B2 (en) | 2012-11-14 | 2017-09-19 | Novartis Ag | Flow promoting ocular implant |
US10617558B2 (en) | 2012-11-28 | 2020-04-14 | Ivantis, Inc. | Apparatus for delivering ocular implants into an anterior chamber of the eye |
US9125723B2 (en) | 2013-02-19 | 2015-09-08 | Aquesys, Inc. | Adjustable glaucoma implant |
US10159600B2 (en) | 2013-02-19 | 2018-12-25 | Aquesys, Inc. | Adjustable intraocular flow regulation |
US9730638B2 (en) | 2013-03-13 | 2017-08-15 | Glaukos Corporation | Intraocular physiological sensor |
JP2016514671A (en) | 2013-03-15 | 2016-05-23 | シナジー ファーマシューティカルズ インコーポレイテッド | Guanylate cyclase agonists and uses thereof |
US9987163B2 (en) | 2013-04-16 | 2018-06-05 | Novartis Ag | Device for dispensing intraocular substances |
JP6574780B2 (en) | 2013-11-14 | 2019-09-11 | アクエシス, インコーポレイテッド | Intraocular shunt inserter |
CA2950187A1 (en) | 2014-05-29 | 2015-12-03 | Glaukos Corporation | Implants with controlled drug delivery features and methods of using same |
US9925088B2 (en) * | 2014-06-06 | 2018-03-27 | Janssen Biotech, Inc. | Sub-retinal tangential needle catheter guide and introducer |
PE20151266A1 (en) * | 2014-07-01 | 2015-09-10 | Velasquez Mario Eduardo Miranda | DRAINAGE DEVICE FOR THE CONTROL OF INTRAOCULAR PRESSURE IN GLAUCOMA |
US10709547B2 (en) | 2014-07-14 | 2020-07-14 | Ivantis, Inc. | Ocular implant delivery system and method |
US10219936B2 (en) * | 2014-09-11 | 2019-03-05 | Orbit Biomedical Limited | Therapeutic agent delivery device with advanceable cannula and needle |
FR3034320B1 (en) | 2015-03-31 | 2017-04-28 | Eye Tech Care | ULTRASOUND TREATMENT OCULAR PROBE |
FR3034308B1 (en) | 2015-03-31 | 2022-01-21 | Philippe Sourdille | OPHTHALMOLOGICAL INTERPOSITION IMPLANT |
CN107835678B (en) | 2015-06-03 | 2021-03-09 | 阿奎西斯公司 | Ex-ocular shunt placement |
EP4265231A3 (en) | 2015-08-14 | 2023-12-20 | Alcon Inc. | Ocular implant with pressure sensor |
WO2017040853A1 (en) | 2015-09-02 | 2017-03-09 | Glaukos Corporation | Drug delivery implants with bi-directional delivery capacity |
US11564833B2 (en) | 2015-09-25 | 2023-01-31 | Glaukos Corporation | Punctal implants with controlled drug delivery features and methods of using same |
WO2017106517A1 (en) | 2015-12-15 | 2017-06-22 | Ivantis, Inc. | Ocular implant and delivery system |
CA3022830A1 (en) | 2016-04-20 | 2017-10-26 | Harold Alexander Heitzmann | Bioresorbable ocular drug delivery device |
AU2017274654A1 (en) | 2016-06-02 | 2018-12-20 | Aquesys, Inc. | Intraocular drug delivery |
JP7015796B2 (en) * | 2016-06-03 | 2022-02-03 | ニュー ワールド メディカル インコーポレイテッド | Intraocular drainage device |
US11246753B2 (en) | 2017-11-08 | 2022-02-15 | Aquesys, Inc. | Manually adjustable intraocular flow regulation |
US10952898B2 (en) | 2018-03-09 | 2021-03-23 | Aquesys, Inc. | Intraocular shunt inserter |
US11135089B2 (en) | 2018-03-09 | 2021-10-05 | Aquesys, Inc. | Intraocular shunt inserter |
CN108433748A (en) * | 2018-04-11 | 2018-08-24 | 中山大学中山眼科中心 | The harvester of liquid sample with valve |
US10369049B1 (en) * | 2018-08-17 | 2019-08-06 | Iridex Corporation | Probes having fiber taper and fluid collection channel for ophthalmic laser treatment |
KR102390116B1 (en) * | 2019-11-19 | 2022-04-25 | 주식회사 마이크로트 | Implant device for lowering intraocular pressure with easy and safe method |
AU2022205382A1 (en) | 2021-01-11 | 2023-06-22 | Alcon Inc. | Systems and methods for viscoelastic delivery |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5411473A (en) * | 1988-10-07 | 1995-05-02 | Ahmed; A. Mateen | Medical valve |
US5454796A (en) * | 1991-04-09 | 1995-10-03 | Hood Laboratories | Device and method for controlling intraocular fluid pressure |
US5476445A (en) * | 1990-05-31 | 1995-12-19 | Iovision, Inc. | Glaucoma implant with a temporary flow restricting seal |
US6007510A (en) * | 1996-10-25 | 1999-12-28 | Anamed, Inc. | Implantable devices and methods for controlling the flow of fluids within the body |
US6077299A (en) * | 1998-06-22 | 2000-06-20 | Eyetronic, Llc | Non-invasively adjustable valve implant for the drainage of aqueous humor in glaucoma |
US6589203B1 (en) * | 2000-01-26 | 2003-07-08 | Peter Mitrev | Glaucoma drainage device implant |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4037604A (en) * | 1976-01-05 | 1977-07-26 | Newkirk John B | Artifical biological drainage device |
US4099529A (en) * | 1976-09-20 | 1978-07-11 | Peyman Gholam A | Wide-angle cutter vitrophage |
US4521210A (en) * | 1982-12-27 | 1985-06-04 | Wong Vernon G | Eye implant for relieving glaucoma, and device and method for use therewith |
US4634418A (en) * | 1984-04-06 | 1987-01-06 | Binder Perry S | Hydrogel seton |
US4604087A (en) * | 1985-02-26 | 1986-08-05 | Joseph Neil H | Aqueous humor drainage device |
NZ215409A (en) * | 1986-03-07 | 1989-02-24 | Anthony Christopher Be Molteno | Implant for drainage of aqueous humour in glaucoma |
US4946436A (en) * | 1989-11-17 | 1990-08-07 | Smith Stewart G | Pressure-relieving device and process for implanting |
US5041081A (en) * | 1990-05-18 | 1991-08-20 | Odrich Ronald B | Ocular implant for controlling glaucoma |
US5171213A (en) * | 1991-08-14 | 1992-12-15 | Price Jr Francis W | Technique for fistulization of the eye and an eye filtration prosthesis useful therefor |
US5346464A (en) * | 1992-03-10 | 1994-09-13 | Camras Carl B | Method and apparatus for reducing intraocular pressure |
US5342370A (en) * | 1993-03-19 | 1994-08-30 | University Of Miami | Method and apparatus for implanting an artifical meshwork in glaucoma surgery |
FR2721499B1 (en) * | 1994-06-22 | 1997-01-03 | Opsia | Trabeculectomy implant. |
US5704907A (en) * | 1994-07-22 | 1998-01-06 | Wound Healing Of Oklahoma | Method and apparatus for lowering the intraocular pressure of an eye |
US6102045A (en) * | 1994-07-22 | 2000-08-15 | Premier Laser Systems, Inc. | Method and apparatus for lowering the intraocular pressure of an eye |
US5601094A (en) * | 1994-11-22 | 1997-02-11 | Reiss; George R. | Ophthalmic shunt |
US5433701A (en) * | 1994-12-21 | 1995-07-18 | Rubinstein; Mark H. | Apparatus for reducing ocular pressure |
US5558630A (en) * | 1994-12-30 | 1996-09-24 | Fisher; Bret L. | Intrascleral implant and method for the regulation of intraocular pressure |
WO1996020742A1 (en) * | 1995-01-06 | 1996-07-11 | Wong Vernon G | Improve eye implant for relief of glaucoma |
FR2747033B1 (en) | 1996-04-03 | 1998-05-22 | Parrat Michel Jesus Hubert | DYNAMIC MEATIC SHUTTER FOR LACRYMAL CANALICLES |
US6142969A (en) * | 1996-10-25 | 2000-11-07 | Anamed, Inc. | Sutureless implantable device and method for treatment of glaucoma |
GB9700390D0 (en) * | 1997-01-10 | 1997-02-26 | Biocompatibles Ltd | Device for use in the eye |
FR2759577B1 (en) * | 1997-02-17 | 1999-08-06 | Corneal Ind | DEEP SCLERECTOMY IMPLANT |
US5882327A (en) * | 1997-04-17 | 1999-03-16 | Jacob; Jean T. | Long-term glaucoma drainage implant |
US5752928A (en) * | 1997-07-14 | 1998-05-19 | Rdo Medical, Inc. | Glaucoma pressure regulator |
EP2260804B2 (en) * | 1999-04-26 | 2022-03-02 | Glaukos Corporation | Trabeculotomy device for treating glaucoma |
US7867186B2 (en) | 2002-04-08 | 2011-01-11 | Glaukos Corporation | Devices and methods for treatment of ocular disorders |
US6699211B2 (en) * | 2000-08-22 | 2004-03-02 | James A. Savage | Method and apparatus for treatment of glaucoma |
EP2039380B1 (en) * | 2002-07-19 | 2012-03-21 | Yale University | Uveoscleral drainage device |
US7604647B2 (en) * | 2004-10-22 | 2009-10-20 | Medical Instrument Development Laboratories, Inc. | Ophthalmic cannula insertion tool and method |
-
2003
- 2003-07-21 EP EP08173090A patent/EP2039380B1/en not_active Expired - Lifetime
- 2003-07-21 AT AT03765883T patent/ATE419026T1/en not_active IP Right Cessation
- 2003-07-21 BR BRPI0312816-4A patent/BR0312816A/en not_active IP Right Cessation
- 2003-07-21 US US10/624,882 patent/US7041077B2/en active Active
- 2003-07-21 AU AU2003256657A patent/AU2003256657A1/en not_active Abandoned
- 2003-07-21 EP EP03765883A patent/EP1534363B1/en not_active Expired - Lifetime
- 2003-07-21 CN CN201010003567A patent/CN101791258A/en active Pending
- 2003-07-21 CN CN03822476A patent/CN100591372C/en not_active Expired - Fee Related
- 2003-07-21 AT AT08173090T patent/ATE550056T1/en active
- 2003-07-21 DE DE60325606T patent/DE60325606D1/en not_active Expired - Lifetime
- 2003-07-21 MX MXPA05000807A patent/MXPA05000807A/en active IP Right Grant
- 2003-07-21 ES ES03765883T patent/ES2320121T3/en not_active Expired - Lifetime
- 2003-07-21 WO PCT/US2003/022832 patent/WO2004008945A2/en not_active Application Discontinuation
- 2003-07-21 CA CA2493010A patent/CA2493010C/en not_active Expired - Fee Related
- 2003-07-21 EP EP10180135A patent/EP2286773B1/en not_active Expired - Lifetime
- 2003-07-21 CA CA2744117A patent/CA2744117A1/en not_active Abandoned
-
2005
- 2005-02-18 ZA ZA200501458A patent/ZA200501458B/en unknown
-
2006
- 2006-03-13 US US11/374,398 patent/US7662123B2/en not_active Expired - Fee Related
- 2006-04-19 HK HK06104686.5A patent/HK1084313A1/en not_active IP Right Cessation
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5411473A (en) * | 1988-10-07 | 1995-05-02 | Ahmed; A. Mateen | Medical valve |
US5476445A (en) * | 1990-05-31 | 1995-12-19 | Iovision, Inc. | Glaucoma implant with a temporary flow restricting seal |
US5454796A (en) * | 1991-04-09 | 1995-10-03 | Hood Laboratories | Device and method for controlling intraocular fluid pressure |
US6007510A (en) * | 1996-10-25 | 1999-12-28 | Anamed, Inc. | Implantable devices and methods for controlling the flow of fluids within the body |
US6077299A (en) * | 1998-06-22 | 2000-06-20 | Eyetronic, Llc | Non-invasively adjustable valve implant for the drainage of aqueous humor in glaucoma |
US6589203B1 (en) * | 2000-01-26 | 2003-07-08 | Peter Mitrev | Glaucoma drainage device implant |
Non-Patent Citations (1)
Title |
---|
See also references of EP1534363A2 * |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7662123B2 (en) | 2002-07-19 | 2010-02-16 | Yale University | Uveoscleral drainage device |
US7282046B2 (en) | 2004-01-22 | 2007-10-16 | Peter M. Adams, Doug P. Adams, and John Sullivan, Collectively as the Stockholder Representative Committee | Glaucoma treatment method |
US10828195B2 (en) | 2006-11-10 | 2020-11-10 | Glaukos Corporation | Uveoscleral shunt and methods for implanting same |
WO2008154502A1 (en) * | 2007-06-07 | 2008-12-18 | Yale University | Uveoscleral drainage device |
US10285853B2 (en) | 2013-03-15 | 2019-05-14 | Glaukos Corporation | Systems and methods for delivering an ocular implant to the suprachoroidal space within an eye |
US11523938B2 (en) | 2013-03-15 | 2022-12-13 | Glaukos Corporation | Systems and methods for delivering an ocular implant to the suprachoroidal space within an eye |
WO2017103818A1 (en) * | 2015-12-16 | 2017-06-22 | Novartis Ag | Devices and methods for a cannula-delivered treatment material application device |
US10500090B2 (en) | 2015-12-16 | 2019-12-10 | Novartis Ag | Devices and methods for a cannula-delivered treatment material application device |
EP3362015B1 (en) * | 2015-12-16 | 2021-04-28 | Alcon Inc. | Devices and methods for a cannula-delivered treatment material application device |
WO2019051475A1 (en) * | 2017-09-11 | 2019-03-14 | Oregon Health & Science University | Glaucoma tube implant with modulated flow |
US11554044B2 (en) | 2017-09-11 | 2023-01-17 | Oregon Health & Science University | Glaucoma tube implant with modulated flow |
Also Published As
Publication number | Publication date |
---|---|
CA2744117A1 (en) | 2004-01-29 |
CN100591372C (en) | 2010-02-24 |
EP2039380A3 (en) | 2011-02-23 |
EP1534363B1 (en) | 2008-12-31 |
EP2039380A2 (en) | 2009-03-25 |
CA2493010C (en) | 2011-09-13 |
ATE550056T1 (en) | 2012-04-15 |
MXPA05000807A (en) | 2005-06-17 |
AU2003256657A1 (en) | 2004-02-09 |
CN1684728A (en) | 2005-10-19 |
CN101791258A (en) | 2010-08-04 |
BR0312816A (en) | 2007-06-26 |
WO2004008945A9 (en) | 2004-06-10 |
EP2286773B1 (en) | 2012-10-17 |
US20060155238A1 (en) | 2006-07-13 |
ES2320121T3 (en) | 2009-05-19 |
ZA200501458B (en) | 2005-09-07 |
HK1084313A1 (en) | 2006-07-28 |
AU2003256657A8 (en) | 2004-02-09 |
EP2286773A1 (en) | 2011-02-23 |
EP1534363A2 (en) | 2005-06-01 |
US7662123B2 (en) | 2010-02-16 |
WO2004008945A3 (en) | 2005-02-03 |
ATE419026T1 (en) | 2009-01-15 |
CA2493010A1 (en) | 2004-01-29 |
US20040015140A1 (en) | 2004-01-22 |
EP2039380B1 (en) | 2012-03-21 |
US7041077B2 (en) | 2006-05-09 |
DE60325606D1 (en) | 2009-02-12 |
EP1534363A4 (en) | 2006-09-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2493010C (en) | Uveoscleral drainage device | |
US20190046355A1 (en) | System and method for treating an ocular disorder | |
JP4688444B2 (en) | Shunt device and method for treating glaucoma | |
US20080306429A1 (en) | Uveoscleral drainage device | |
US7641627B2 (en) | Method and apparatus for reducing intraocular pressure | |
US20130281910A1 (en) | Ocular implant system | |
US20210177657A1 (en) | Ocular device for treating glaucoma and related minimally invasive glaucoma surgery method | |
EP1707166A1 (en) | Irrigation tip | |
US20090177138A1 (en) | Shunt Device for Glaucoma Treatment | |
WO2002080829A2 (en) | Method and apparatus for treatment of glaucoma | |
JP2005508213A (en) | Methods and intrascleral implants for the treatment of glaucoma and presbyopia |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
COP | Corrected version of pamphlet |
Free format text: PAGES 1/7-7/7, DRAWINGS, REPLACED BY NEW PAGES 1/7-7/7; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2005/000807 Country of ref document: MX Ref document number: 2493010 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003765883 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005/01458 Country of ref document: ZA Ref document number: 200501458 Country of ref document: ZA |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 20038224763 Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 2003765883 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: JP |
|
ENP | Entry into the national phase |
Ref document number: PI0312816 Country of ref document: BR |